AIM - AIM ImmunoTech to recruit long-term COVID-19 patients with chronic fatigue in Ampligen trial

The independent Institutional Review Board has granted approval to AIM ImmunoTech ([[AIM]] +3.8%)  to widen the  trial for its drug candidate Ampligen and include people suffering from long-term effects of the coronavirus (COVID-19).The group, known as COVID-19 ‘long haulers’ as they continue to show chronic fatigue-like symptoms for months after officially recovering from their initial illness, will be included in the clinical trial for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)Up to 20 of the 100 active participants can be long haulers, according to the new trial protocol amendment, and the firm is now preparing the IRB-approved protocol for submission to the FDA.In June, the company filed a provisional utility patent application for Ampligen to be used as a possible treatment for chronic fatigue associated with COVID-19.

For further details see:

AIM ImmunoTech to recruit long-term COVID-19 patients with chronic fatigue in Ampligen trial